Skip to main content
. Author manuscript; available in PMC: 2011 Aug 23.
Published in final edited form as: Cancer Res. 2008 Apr 1;68(7):2321–2328. doi: 10.1158/0008-5472.CAN-07-5031

Figure 6.

Figure 6

In vivo studies of ABT-737 or etoposide in LX33 primary xenografts (A) or ABT-737, etoposide or combination of ABT-737 and etoposide in LX22 (B) and LX36 (C) primary xenografts. Tumor growth of SCLC primary xenografts on mice treated with vehicle control (blue), ABT-737 (yellow) at 100 mg/kg/d i.p. for 21 d, etoposide (red) at 12 mg/kg/d for days 1, 4, and 9 or ABT-737 plus etoposide (green). X axis, days after the initiation of treatment.